Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-07-12
2005-07-12
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S184100, C424S246100, C530S300000
Reexamination Certificate
active
06916474
ABSTRACT:
The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities forBacillus anthracisantigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection byBacillus anthracis.
REFERENCES:
patent: 5601823 (1997-02-01), Williams et al.
patent: 6329156 (2001-12-01), Cirino et al.
patent: WO 99/36569 (1999-01-01), None
Thomas E. Creighton, in his book “Protein Structure: A Practical Approach, 1989; pp. 184-186”.
Thomas E. Creighton, in his book, “Proteins: Structures and Molecular Properties, 1984”, (pp. 314-315).
Nosoh, Y. et al in “Protein Stability and Stabilization through Protein Engineering, 1991” (chapter 7, p. 197, second paragraph).
Maynard et al (Nature Biotechnology, vol. 20, Jun. 2002).
Bradley et al.,Nature, “Identification of the cellular receptor for anthrax toxin,” 8;414(6860):225-229, 2001.
Bull and Parrich, “A binding contract for anthrax,”Science, 297:201-202, 202.
Chen and Okayama, “High-efficiency transformation of mammalian cells by plasmid DNA,”Mol. Cell Biol.,7(8):2745-2752, 1987.
Chen et al., “Isolation of high-affinity ligand-binding proteins by periplasmic expression with cyto metric screening,”Nat. Biotechnol.,19:537-542, 2001.
Chen et al., “In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site,”Protein Eng.,12:349-356, 1999.
Daughterty et al., “Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies,”Proc. Natl. Acad. Sci.,USA, 97:2029-2034, 2000.
Ezzell et al., “Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components ofBacillus anthracistoxin,”Infect. Immun.,45:761-777, 1984.
Georgiou et al., “Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines,”Nat. Biotechnol.,15:29-34, 1997.
Hayhurst and Georgiou,. “High throughput isolation,”Curr. Opin. Chem. Biol.,5:683-689, 2001.
Hayhurst and Harris, “Escherichia coliSkp chaperone coexpression improves solubility and phage display of single-chain antibody fragments,”Protein Expr. Purif.,15:336-343, 1999.
Hayhurst et al., “Isolation and expression of recombinant antibody fragments to the biological warfare pathogenBrucella melitensis,” J. Immunol. Methods, 276:185-196, 2003.
Hayhurst, “mproved expression characteristics of single-chain Fv fragments when fused downstream of theEscherichia colimaltos-binding protein or upstream of a single immunoglobulin-constant domain,”Protein Expr. Purif.,18:1-10, 2000.
Hoess, “Protein design and phage display,”Chem. Rev.,101:3205-3218, 2001.
Ivins et al., “Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin,”Applies and Environmental Microbiology,55:2098-2100, 1989.
Keller and Stiehm, “Passive immunity in prevention and treatment of infectious diseases,”Clin. Microbiol. Reviews, 13:602-614, 2000.
Krebber et al., “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system,”J. Immunol. Methods,201:35-55, 1997.
Leppla, “Anthrax toxin,” Chapter 19 In:Handbook of Experimental Pharmacology,145:445-472, 2000.
Li et al., “X-ray snapshots of the maturation of an antibody response to a protein antigen,”Nat. Struct. Biol.,10(6):482-488, 2003.
Little et al., “Characterization of lethal factor binding and cell receptor binding domains of protective antigen ofBacillus antracisusing monoclonal antibodies,”Microbiology,142:707-715, 1996.
Little et al., “Passive protection by polyclonal antibodies againstBacillus antracisinfection in guinea pigs,”Infection and Immunity,65:5171-5175, 1997.
Little et al., “Production and characterization of monoclonal antibodies to the protective antigen component ofBacillus anthracistoxin,”Infect. Immun.,56:1807-1813, 1988.
Maynard et al., “Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity,”Nat. Biotechnol.,20:597-601, 2002.
Mourez et al., “Designing a polyvalent inhibitor of anthrax toxin,”Nature Biotechnology,19:958-961, 2001.
Pitt et al., “In vitro correlate of immunity in a rabbit model of inhalational anthrax,” Vaccine, 19:4768-4773, 2001.
Sellman et al., “Dominant-nagative mutants of a toxin subunit: an approach to therapy of anthrax,”Science, 292:695-697, 2001.
Singh et al., “A dominant nagative mutant ofBacillus antracisprotective antigen inhibits anthrax toxin in vivo,”J. of Biol. Chem.,276:22090-22094, 2001.
Turnbill et al., “Antibodies to Anthrax Toxin in Humans and Guinea Pigs and Their Relevance to Protective Immunity,” Abstract,Med. Microbiol. Immunol.,177:293-303, 1988.
U.S. Appl. No. 10/288,269, filed Nov. 5, 2002, (UTSB:720US).
Wittrup, “The single cell as a microplate well,”Nat. Biotechnol.,18:1039-1040, 2000.
Georgiou George
Harvey Barrett R.
Iverson Brent L.
Board of Regents , The University of Texas System
Ford Vanessa L.
Fulbright & Jaworski L.L.P.
Smith Lynette R. F.
LandOfFree
Antibodies with increased affinities for anthrax antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies with increased affinities for anthrax antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies with increased affinities for anthrax antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423210